History
C3 was formed from the WA Skin Culture Unit, a hospital based department that provided autologous cells for the entire Western Australian burns community.
During early stages of development, the WA Skin Culture Unit was able to introduce innovative culture technologies that resulted in the evolution of cell suspensions that enabled surgeons to treat major burns and trauma within five to seven days.
1898
Discovery that skin fragments could be kept alive for extended periods of time and in some cases, be re-transplanted back to the donor.
1981
The first reported use of Cultured Epithelial Autograft (CEA) sheets in humans.
1990
The first patient treated with CEA sheets in Perth, Western Australia.
1993
Foundation of the WA Skin Culture Unit at Princess Margaret Hospital for Children, Perth, Western Australia. The unit also serviced the Royal Perth Hospital, Western Australia's premier trauma referral centre.
1999
In January, The McComb Foundation was founded to advance the research and development of innovative skin culture technologies.
1999
Clinical Cell Culture (C3) was founded with the aim to commercialise technology developed by the McComb Foundation.
2000
C3 established its laboratories in Technology Park, Bentley Western Australia and commenced construction of a dedicated skin culture laboratory./p>
2001
The WA Skin Culture Unit relocated to C3's new laboratory in Bentley.
CellSpray® became commercially available.
ECAT Development Capital became a core investor of C3.
2002
June - ReCell® became available in Australia on a compassionate basis under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).
September - CellSpray® XP was used for the first time during a major terrorist incident, providing multiple patients with an autologous cell suspension within 48-hours.
November - ECAT Development Capital acquired Clinical Cell Culture Pty Ltd and listed a company, Clinical Cell Culture Ltd on the Australian Stock Exchange (ASX). C3 Operations Pty Ltd became a wholly owned subsidiary of the publicly listed holding company, Clinical Cell Culture Ltd.
2003
C3 opened its European office and began trading under the name C3 Europe Ltd.
C3 signed an agreement with Ventrex Corp., USA to develop components of the ReCell® kit to enable mass production.
C3 signed an agreement with Cambrex Bio Science to contract manufacture CellSpray® products in Belgium for European distribution.
2004
January - CellSpray receives European approvals
February - CellSpray® to be used in The Netherlands and Denmark
March - Clinical Cell Culture becomes ISO 13485 certified. The Swiss Federal Office of Public authorised the supply of CellSpray® XP in Switzerland
July - approval received from the Belgian Health Authorities for Cambrex, C3's European Contract Manufacturer, to manufacture CellSpray® and CellSpray® XP on behalf of C3.
August - British Medicines and Healthcare Products Regulatory Agency authorises the supply of CellSpray® and CellSpray® XP in the United Kingdom
October - C3's corporate office relocates to Cambridge, UK.
2005
January - co-founder and Director, Fiona Wood is named Australian of the Year
February - C3's quality system re-certified to ISO 13486 by SGS
March - First Japanese delivery and usage of ReCell®
March - European regulatory approval obtained for ReCell®
March - First European stocking orders for ReCell®
June - C3 launches CellSpray® XP commercially in Europe
June - ReCell® launched in Europe at EURAPS Meeting in Marseilles, France
July - First CellSpray® XP patient treated in Europe
